Arch Therapeutics Completes Financing as Bridge to Uplisting
Common Stock Listing on National Exchange is Next Planned Significant MilestoneFRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Arch Therapeutics,…
Pharmaceuticals, Biotechnology and Life Sciences
Common Stock Listing on National Exchange is Next Planned Significant MilestoneFRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Arch Therapeutics,…
Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial PerformanceFirst half 2023 total revenues with…
TOKYO and SEATTLE, Sept. 07, 2023 (GLOBE NEWSWIRE) — Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company…
AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate…
Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J.,…
THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the…
Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., Sept. 07, 2023…
— Recorded First Quarter Revenue of $37.7 Million — — Signed $36 Million in Net New Business Orders Resulting in…
Assignment results in estimated cumulative cash savings of more than $30M andĀ supports projected cash runway to mid-2026REDWOOD CITY, Calif., Sept.…
EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT), a clinical-stage biotherapeutics company harnessing…